Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

CLL International Prognostic Index (CLL-IPI)

The CLL-IPI integrates clinical stage with biological markers to stratify chronic lymphocytic leukaemia patients into four risk groups, developed from pooled data of 3,472 patients.

Evidence-based context for fast calculator use

Purpose:
Predict overall survival in CLL and guide treatment timing decisions
Population:
Patients with chronic lymphocytic leukaemia (CLL)
Factors:
TP53 status (del(17p)/mutated), IGHV mutation status, β2-microglobulin, Clinical stage (Binet/Rai), Age
Reference:
International CLL-IPI Working Group, Lancet Oncology 2016
HomeCLL-IPI
Pin your most used calculators here by clicking the star in the dropdown.

CLL-IPI

Clinical Context & Background

The CLL-IPI combines genetic, biochemical, and clinical parameters to stratify survival in CLL patients. It is useful for counseling patients and designing clinical trials.
Primary Source EvidenceInternational CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
Formula Logic
Sum of weighted points: TP53(4), IGHV(2), B2M(2), Stage(1), Age(1).

Reference Data

Risk GroupScore5-Year Overall Survival
Low Risk0 - 193.2%
Intermediate Risk2 - 379.3%
High Risk4 - 663.3%
Very High Risk7 - 1023.3%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use CLL-IPI when cLL-IPI stratifies 5-year overall survival in Chronic Lymphocytic Leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age to guide therapy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through Very High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify TP53 status, IGHV Mutational Status, Beta-2 Microglobulin > 3.5 mg/L?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)MIPI (Mantle Cell Lymphoma)IPS (Hodgkin Lymphoma)

Frequently Asked Questions

When should CLL-IPI be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can CLL-IPI determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.